Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 in Benign Prostatic Hyperplasia
NCT02855892Phase 2Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tertomotide in benign prostatic hyperplasia (BPH), sponsored by GemVax & KAEL Co., Ltd.. Started Oct 2015; status: completed.
02
Drugs
tertomotide
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02855892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02855892.